Special Alert ----
Dec. 18, 1996
Certain high-risk patients -- those with chronic heart or
lung diseases or those who are immune suppressed -- may have
received subpotent influenza vaccine and should consider additional
vaccination according to the Food and Drug Administration.
FDA emphasized that since some protection probably exists
from the first injection, priority should be given to any
high-risk patient who hasn't yet had a flu shot over anyone
being considered for a second shot.
Eleven batches of Parke Davis' Fluogen are in question. Parke
Davis recalled those batches last month upon discovering the
protection against the Nanchang flu, a new strain of the usually
harsh Type A flu, wasn't as potent as thought. According to
reports, the Centers for Disease Control and Prevention studied
elderly nursing home residents in New York and found those
who got the recalled vaccine produced 39 percent fewer flu
antibodies than nursing home residents who got another manufacturer's
vaccine. A separate CDC study of healthy young health-care
workers found no difference in antibody levels between the
recalled and more potent vaccines. Healthy individuals who
aren't at risk for flu complications do not need a second
Recalled vaccine lots are: 00176P, 00276P, 00576P, 00586P,
00676P, 00686P, 00786P, 00886P, 00966P, 00986P and 01066P.